Company: Selecta Biosciences Inc.
Job title: Chief Scientific Officer
Dr. Kishimoto is the Chief Scientific Officer of Selecta Biosciences, a biotechnology company developing synthetic vaccines based on a novel self-assembling nanoparticle technology. Prior to joining Selecta, Dr. Kishimoto was Vice President of Research at Momenta Pharmaceuticals where he led multidisciplinary teams in inflammation, oncology, and cardiovascular disease. Previously he was Senior Director of Inflammation Research at Millennium Pharmaceuticals, where he provided the scientific leadership for four programs in clinical development, and an Associate Director of Immunology at Boehringer Ingelheim. Dr. Kishimoto received his doctoral degree in Immunology from Harvard University and his post-doctoral training at Stanford University.
Live Q&A – Ask the speakers your questions 11:20 am
day: Day Two
Addressing the Need & Potential Solution for AAV Redosing 10:30 am
• Factors that may contribute to the need for AAV re-dosing include insufficient therapeutic activity of the initial dose, growth of the target organ in pediatric patients, inflammation or tissue injury that causes cell turnover, or desire to split a large vector dose over multiple smaller doses • ImmTOR technology has been shown to mitigate…Read more
day: Day Two